Verona Pharma plc Board of Directors

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

Dr. David S. Zaccardelli Pharm.D.

Dr. David S. Zaccardelli Pharm.D.

President, CEO & Executive Director

Ms. Caroline Diaz

Ms. Caroline Diaz

Senior Vice President of Regulatory Affairs

Ms. Ostra Jewell

Ms. Ostra Jewell

Senior Vice President of Human Resources

Ms. Victoria Stewart

Ms. Victoria Stewart

Director of Communications

Mr. Christopher Martin

Mr. Christopher Martin

Chief Commercial Officer

Mr. Matthew Casbon

Mr. Matthew Casbon

VP of Sales, Marketing & Training

Mr. Mark W. Hahn

Mr. Mark W. Hahn

Chief Financial Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.